We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center.
- Authors
Rimini, Margherita; Pecchi, Annarita; Prampolini, Francesco; Bussei, Chiara; Salati, Massimiliano; Forni, Daniela; Martelli, Francesca; Valoriani, Filippo; Canino, Fabio; Bocconi, Alessandro; Gelsomino, Fabio; Reverberi, Linda; Benatti, Stefania; Piacentini, Federico; Menozzi, Renata; Dominici, Massimo; Luppi, Gabriele; Spallanzani, Andrea
- Abstract
Background: Few data about the link between nutritional status and survival are available in the metastatic gastric cancer (GC) setting. The aim of this work was to evaluate the prognostic role of tissue modifications during treatment and the benefit of a scheduled nutritional assessment in this setting. Methods: Clinical and laboratory variables of 40 metastatic GC patients treated at Modena Cancer Center were retrieved: 20 received a nutritional assessment on the oncology's discretion, the other 20 received a scheduled nutritional assessment at baseline and every 2–4 weeks. Anthropometric parameters were calculated on Computed Tomography (CT) images at the baseline and after 3 months of chemotherapy. Results: A correlation between baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS), Lymphocyte to Monocyte Ratio (LMR), C-reactive protein (PCR), Prognostic Nutritional Index (PNI) and Overall survival (OS) was highlighted. Among the anthropometric parameters, early skeletal muscle mass depletion (ESMMD) >10% in the first months of treatment significantly impacted on mOS (p = 0.0023). A link between ESMMD and baseline LDH > 460 U/L, baseline CRP > 2.2 mg/dL and weight decrease during treatment emerged. Patients evaluated with a nutritional scheduled support experienced a mean gain in subcutaneous and visceral fat of 11.4% and 10.21%, respectively. Conclusion: We confirm the prognostic impact of ESMMD > 10% during chemotherapy in metastatic GC. The prognostic role of a scheduled nutritional assessment deserves further confirmation in large prospective trials.
- Subjects
MUSCLE mass; STOMACH cancer; SKELETAL muscle; NUTRITIONAL assessment; OVERALL survival
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 8, p1705
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10081705